Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Finished Goods (2016 - 2018)

Sanofi's Finished Goods history spans 4 years, with the latest figure at $2.7 billion for Q4 2018.

  • For Q4 2018, Finished Goods rose 6.3% year-over-year to $2.7 billion; the TTM value through Dec 2018 reached $2.7 billion, up 6.3%, while the annual FY2018 figure was $2.8 billion, 14.71% up from the prior year.
  • Finished Goods for Q4 2018 was $2.7 billion at Sanofi, up from $2.5 billion in the prior quarter.
  • Across five years, Finished Goods topped out at $2.7 billion in Q4 2018 and bottomed at $2.3 billion in Q4 2015.
  • The 4-year median for Finished Goods is $2.4 billion (2017), against an average of $2.5 billion.
  • The largest annual shift saw Finished Goods grew 1.88% in 2016 before it rose 10.02% in 2017.
  • A 4-year view of Finished Goods shows it stood at $2.3 billion in 2015, then increased by 1.88% to $2.3 billion in 2016, then rose by 10.02% to $2.5 billion in 2017, then grew by 6.3% to $2.7 billion in 2018.
  • Per Business Quant, the three most recent readings for SNY's Finished Goods are $2.7 billion (Q4 2018), $2.5 billion (Q4 2017), and $2.3 billion (Q4 2016).